Abstract

For women with lymph node (ln)-positive, estrogen receptor-positive, and her2 (human epidermal growth factor receptor 2)-negative breast cancer (bca), current guidelines recommend treatment with both hormonal therapy and chemotherapy. The 21-gene Recurrence Score (rs) assay might be helpful in selecting patients with bca who can be spared chemotherapy when they have 1-3 positive lns and a lower risk of recurrence. In the present study, we performed a cost-utility analysis comparing use of the 21-gene rs assay with current practice from the perspective of a Canadian health care payer. A Markov model was developed to determine costs and quality-adjusted life-years (qalys) over a patient's lifetime. Patient outcomes in both study groups were examined based on published clinical trials. Costs were derived primarily from published Canadian sources. Costs and outcomes were discounted at 1.5% annually, and costs are reported in 2016 Canadian dollars. A probabilistic analysis was used, and the model parameters were varied in a sensitivity analysis. The results indicate that use of the 21-gene rs assay was less costly ($432 less) and more effective (0.22 qalys) than current practice. The probabilistic analysis revealed that 70% of the 10,000 simulated incremental cost-effectiveness ratios were in the southeast quadrant. The results were sensitive to the probability of a low rs and to the probability of receiving chemotherapy in the low-risk rs category and in current practice. Use of the 21-gene rs assay could be a cost-effective strategy for Ontario patients with estrogen receptor-positive, her2-negative early bca and 1-3 positive lns.

Highlights

  • Breast cancer is the most common cancer and the 2nd leading cause of death from cancer among Canadian women[1]

  • The results indicate that use of the 21-gene rs assay was less costly ($432 less) and more effective (0.22 qalys) than current practice

  • The results were sensitive to the probability of a low rs and to the probability of receiving chemotherapy in the low-risk rs category and in current practice

Read more

Summary

Introduction

Breast cancer (bca) is the most common cancer and the 2nd leading cause of death from cancer among Canadian women[1]. For women with lymph node (ln)–positive, estrogen receptor (er)–positive bca, current guidelines recommend treatment with both hormonal therapy and chemotherapy[2,3]. The 21-gene rs assay might be helpful in selecting patients with a lower risk of recurrence, for whom chemotherapy could be omitted. For women with lymph node (ln)–positive, estrogen receptor–positive, and her[2] (human epidermal growth factor receptor 2)–negative breast cancer (bca), current guidelines recommend treatment with both hormonal therapy and chemotherapy. The 21-gene Recurrence Score (rs) assay might be helpful in selecting patients with bca who can be spared chemotherapy when they have 1–3 positive lns and a lower risk of recurrence. 70% of those in the highrisk rs category received 6 cycles of fec-d: 3 cycles of 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2, followed by 3 cycles of docetaxel 100 mg/m2 (clinical expert opinion, 2018). All patients in that category who received chemotherapy were treated with 4 cycles of tc chemotherapy

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call